致力于改善糖尿病患者的伤口不愈合:Ilya Pharma获得530万欧元的融资

2020-06-10 MedSci原创 MedSci原创

ILP100通过将趋化因子CXCL12直接递送到患病部位,来减轻炎症并帮助加速伤口愈合和恢复。

Ilya Pharma是一家临床阶段的生物制药公司,正在利用其ILP技术平台开发趋化因子基因疗法,今天宣布从欧洲创新委员会(EIC)加速器混合融资计划中获得总计530万欧元的资金。这笔资金将使Ilya Pharma加速其领先候选药物ILP100的II期试验,该药物有望治愈糖尿病患者无法愈合的伤口。

See the source image

有18%的糖尿病患者患有慢性伤口,仅在欧洲就至少有600万人。这也是糖尿病的并发症之一,尤其是下肢无法愈合的伤口会导致截肢,截肢后一年内的死亡率为30%。然而如今的治疗仅限于机械清创术,使用不同的敷料以及大量使用抗生素

Ilya Pharma开发的新疗法ILP100通过将趋化因子CXCL12(CXC motif ligand 12)直接递送到患病部位,来减轻炎症并帮助加速伤口愈合和恢复。

由于趋化因子的半衰期短,Ilya公司是使用转基因的乳酸菌作为微型生物反应器,来实现趋化因子的局部递送。在ILP100中,乳杆菌表达人趋化因子CXCL12。将乳杆菌冷冻干燥在局部给药之前用水使其复活。

Ilya Pharma首席执行官EvelinaVågesjö博士说:“我们很高兴获得欧洲创新委员会的资助,相信我们的新疗法将为改善糖尿病、手术后伤口和胃肠道适应症(如IBD)等患者的生活质量提供了一个真正的机会。”

原始出处:

https://www.firstwordpharma.com/node/1731316?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787670, encodeId=89981e876704a, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 09 02:05:44 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908593, encodeId=b27319085935a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jun 29 08:05:44 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459100, encodeId=3be81459100b1, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Fri Jun 12 07:05:44 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474940, encodeId=7c3e14e494063, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jun 12 07:05:44 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043153, encodeId=181a104315372, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 10 19:05:44 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048142, encodeId=61111048142e0, content=又是钱!医学需要投资呀,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Jun 10 19:05:44 CST 2020, time=2020-06-10, status=1, ipAttribution=)]
    2020-12-09 jj000001
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787670, encodeId=89981e876704a, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 09 02:05:44 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908593, encodeId=b27319085935a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jun 29 08:05:44 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459100, encodeId=3be81459100b1, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Fri Jun 12 07:05:44 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474940, encodeId=7c3e14e494063, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jun 12 07:05:44 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043153, encodeId=181a104315372, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 10 19:05:44 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048142, encodeId=61111048142e0, content=又是钱!医学需要投资呀,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Jun 10 19:05:44 CST 2020, time=2020-06-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787670, encodeId=89981e876704a, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 09 02:05:44 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908593, encodeId=b27319085935a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jun 29 08:05:44 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459100, encodeId=3be81459100b1, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Fri Jun 12 07:05:44 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474940, encodeId=7c3e14e494063, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jun 12 07:05:44 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043153, encodeId=181a104315372, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 10 19:05:44 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048142, encodeId=61111048142e0, content=又是钱!医学需要投资呀,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Jun 10 19:05:44 CST 2020, time=2020-06-10, status=1, ipAttribution=)]
    2020-06-12 zhao4618
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787670, encodeId=89981e876704a, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 09 02:05:44 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908593, encodeId=b27319085935a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jun 29 08:05:44 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459100, encodeId=3be81459100b1, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Fri Jun 12 07:05:44 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474940, encodeId=7c3e14e494063, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jun 12 07:05:44 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043153, encodeId=181a104315372, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 10 19:05:44 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048142, encodeId=61111048142e0, content=又是钱!医学需要投资呀,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Jun 10 19:05:44 CST 2020, time=2020-06-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1787670, encodeId=89981e876704a, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 09 02:05:44 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908593, encodeId=b27319085935a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jun 29 08:05:44 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459100, encodeId=3be81459100b1, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Fri Jun 12 07:05:44 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474940, encodeId=7c3e14e494063, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jun 12 07:05:44 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043153, encodeId=181a104315372, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 10 19:05:44 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048142, encodeId=61111048142e0, content=又是钱!医学需要投资呀,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Jun 10 19:05:44 CST 2020, time=2020-06-10, status=1, ipAttribution=)]
    2020-06-10 misszhang

    谢谢MedSci提供最新的资讯

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1787670, encodeId=89981e876704a, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 09 02:05:44 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908593, encodeId=b27319085935a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jun 29 08:05:44 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459100, encodeId=3be81459100b1, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Fri Jun 12 07:05:44 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474940, encodeId=7c3e14e494063, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jun 12 07:05:44 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043153, encodeId=181a104315372, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 10 19:05:44 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048142, encodeId=61111048142e0, content=又是钱!医学需要投资呀,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Jun 10 19:05:44 CST 2020, time=2020-06-10, status=1, ipAttribution=)]
    2020-06-10 CHANGE

    又是钱!医学需要投资呀,赞!

    0

相关资讯

Brit J Cancer:糖尿病与前列腺癌风险的关系

该研究除了为糖尿病和前列腺癌之间的负性关联提供了进一步的证据外,该研究还是第一个报道糖尿病与ERG/PTEN前列腺癌之间关联的研究。

J Peiodontal Res:天然姜黄素对糖尿病大鼠实验性牙周炎进展的影响

本实验旨在评估天然姜黄素(CURC)在患有糖尿病(DM)的动物的实验性牙周炎(EP)中的作用。

JCEM:补充维生素D对糖尿病发病率的影响

在糖尿病前期患者中,与安慰剂相比,中等至高剂量(> 1000IU/d)而不是低剂量维生素D补充可显著降低T2DM的发病风险。

Nature子刊:蜗牛的“致命毒液”成“救命良药”,迄今最小胰岛素有望彻底治疗糖尿病

发现胰岛素将近一个世纪之后,由美国犹他大学健康研究所(U of U Health)的科学家领导的国际研究小组开发出了结构最小但功能齐全的胰岛素。它基于捕鱼的锥形蜗牛产生的速效毒液胰岛素,同时也显示出人

配方膳食可减重,并预防糖尿病!柳叶刀随机对照研究

近年来,2型糖尿病发病呈年轻化趋势。近日,柳叶刀杂志发表一项随机对照研究显示,在糖尿病早期(3年内),包括配方低能量膳食替代产品在内的强化生活方式干预,可以显着降低体重,改善血糖水平。

Nat Struc Mole Bio:蜗牛的“致命毒液”成“救命良药”,迄今最小胰岛素有望彻底治疗糖尿病

导言:海洋生物锥形蜗牛(鸡心螺,cone snail),迅速射出的毒液可让受伤者一命呼呜。来自美国和澳大利亚的研究人员利用其“迅雷不及掩耳之势”,作为新药“缪斯&r